ATryn (antithrombin alfa)
Exceptional circumstancesAdditional monitoring
- Region
- 🇪🇺 EU
- Active substance
- antithrombin alfa
- Company
- Laboratoire Francais du Fractionnement et des Biotechnologies
- Status
- Withdrawn
- Therapeutic area
- Antithrombin III Deficiency
- EU approval
- Fri 28 Jul 2006
- Designations
- Exceptional circumstances, Additional monitoring
- Application
- EMEA/H/C/000587
- ATC
- B01AB02
- Official record
- www.ema.europa.eu
Indication
ATryn is indicated for the prophylaxis of venous thromboembolism in surgery of patients with congenital antithrombin deficiency. ATryn is normally given in association with heparin or low molecular weight heparin.
Regulatory milestones
No milestones recorded in the last year.
Follow ATryn
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.